Sarcomatoid renal-cell carcinoma: treatment strategy, review of the literature and a case report
Journal Title: OncoReview - Year 2016, Vol 6, Issue 4
Abstract
Introduction: Sarcomatoid renal-cell carcinoma is a very rare cancer characterised with aggressive course of disease and poor prognosis. At present there are no standards of care for this histologic subtype of renal cell carcinoma resistant to various forms of systemic treatment.
Authors and Affiliations
Agnieszka Gębara-Puchniarz, Beata Hryciuk, Rafał Stec, Cezary Szczylik, Bartłomiej Grala, Wojciech Kozłowski
Keywords
Related Articles
- EP ID EP186909
- DOI 10.5604/01.3001.0009.5066
- Views 225
- Downloads 0
Tyrosine kinase inhibitors – should we worry about cardiovascular complications?
Small-molecular tyrosine kinase inhibitors constitute an effective therapeutic option in patients with hematologic malignancies and solid tumours. On the other hand, the significance of cardiovascular adverse events asso...
Pericardiocentesis and pericardial therapy aspects in cancer patients - a case report
The malignancy related pericardial effusion has variable dynamics, and the clinical presentation and severity of symptoms are directly related to the degree of hemodynamic conditions and the rate of fluid accumulation in...
Ifosfamide-induced encephalopathy in a patient with metastatic fibrosarcoma
Ifosfamide is a cytostatic drug commonly used in chemotherapy. One of the common adverse effects resulting from the treatment with ifosfamide is encephalopathy. This paper describes a case study of a 64-year-old patient...
Zasady postępowania diagnostyczno-terapeutycznego u chorych na nowotwory podścieliskowe przewodu pokarmowego (GIST) w 2010 roku
Nowotwory podścieliskowe przewodu pokarmowego (ang. gastrointestinal stromal tumors, GIST) są najczęstszymi nowotworami pochodzenia mezenchymalnego w obrębie przewodu pokarmowego. Nowotwory te, dzięki postępom w diagnost...
Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group
Purpose: Somatostatin analogs are indicated for symptom control in patients with gastroenteropancreatic neuroendocrine tumors (NETs). The ability of somatostatin analogs to control the growth of well-differentiated metas...